In vitro activity of tebipenem and comparator agents against bacterial pathogens isolated from patients with cancer Authors: Bahgat Gerges, Joel Rosenblatt, Samuel A Shellburne, Anne-Marie Chaftari, Ray Hachem, Issam Raad Published: 2023 ABSTRACT AbstractBackgroundTebipenem is a broad-spectrum orally administered carbapenem antibiotic that could be an alternative to IV carbapenems. The current study evaluated in vitro activity of tebipenem against bacterial isolates recovered from patients with cancer.MethodsA total of 611 bacterial pathogens recently isolated from patients with cancer were tested for susceptibility to tebipenem and comparators. CLSI-approved broth microdilution methods were used. MIC50, MIC90, MIC range and percentage susceptibility calculations were made using FDA breakpoints when available.ResultsTebipenem had a low MIC90 for most Gram-positive and Enterobacterales isolates. Tebipenem MIC90 ranged from 0.06 to 0.25 mg/L for all tested Enterobacterales.ConclusionsOral tebipenem has promising activity against clinically significant bacterial pathogens isolated from patients with cancer. Further clinical evaluation of tebipenem for the treatment of bacterial infections in patients with cancer is warranted. Introduction For more than seven decades, β-lactam antibiotics have been successfully used for the treatment of bacterial infection, particularly in high-risk cancer patients.1 However, resistance to these compounds is increasing, primarily through the emergence of β-lactamase enzymes that hydrolyse the β-lactam ring, rendering the drugs inactive.2 Carbapenems are an important subclass of β-lactam antibiotics that protect the partner β-lactam ring.3,4 Carbapenems (such as imipenem, meropenem and ertapenem) have been proven to have a wider spectrum against bacteria than other β-lactams such as cephalosporins. Carbapenems have been observed to be safe and have emerged as the standard of care for many MDR Gram-negative bacterial infections; however, carbapenems are available only as IV therapeutics for such indications.4 Many countries have reported a rapid increase in the number of ESBL-producing and fluoroquinolone-resistant Escherichia coli specimens isolated from ill patients admitted to hospital settings, and this has become an emerging public health concern, especially for high-risk patients such as those with cancer.5 Patients with severe infections due to ESBL-producing and fluoroquinolone-resistant isolates often require hospitalization and treatment with parenteral carbapenems.6 Some oral antibiotics, such as nitrofurantoin and fosfomycin trometamol, are active against ESBL-producing E. coli isolates, but these antibiotics are usually effective only for the treatment of uncomplicated lower urinary tract infections, such as acute cystitis. These agents do not achieve high plasma levels and thus are not indicated for the treatment of upper urinary tract infections, including acute pyelonephritis.5 Therefore, more effective oral antibiotics against urinary tract infections due to ESBL-producing isolates are needed. Tebipenem pivoxil hydrobromide is a broad-spectrum orally administered antibiotic from the carbapenem subgroup of β-lactam antibiotics that could be an alternative to IV carbapenem antibiotic therapy. Tebipenem pivoxil hydrobromide is rapidly converted to active tebipenem in plasma by enterocytes.7 In the current study, we evaluated the in vitro activity of tebipenem compared with other agents against clinical isolates recovered exclusively from patients with cancer being treated at our institution. Materials and methods We tested a total of 611 organisms, 300 Gram-positive organisms (GPO) and 311 Gram-negative bacilli (GNB) recently isolated (2019–22) from patients being treated at The University of Texas MD Anderson Cancer Center. These bacteria were isolated exclusively from blood cultures collected from patients with cancer treated at our institution, processed in our institution’s clinical microbiology laboratory, stored in our Institutional Review Board-approved research repository (PA13-0334), and revived for testing as needed. Identity of each isolate was determined by MALDI-TOF. Only one isolate per patient was tested (i.e. no duplicate or serial isolates). These de-identified isolates were sequentially selected by their most recent collection date without any intentional bias to include prespecified quotas by species based on susceptibility characteristics. Tebipenem powder was provided by the sponsor, Spero Pharmaceuticals. Comparator agents were purchased from reliable commercial sources for in vitro testing. Comparator agents for GPO included cefepime, meropenem, levofloxacin, daptomycin, linezolid and vancomycin. Comparator agents for GNB included cefepime, meropenem, trimethoprim/sulfamethoxazole, levofloxacin, amikacin and ertapenem. Susceptibility testing was performed using CLSI-approved broth microdilution methodology.8 ATCC control organisms (E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 for GNB and Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 for GPO) were included in each experiment to ensure the accuracy, potency of agents, and validity of our results. The in vitro activity of each agent was reported using MIC. MIC50, MIC90, MIC range and percentage susceptibility calculations were made using FDA breakpoints when ≥10 isolates of a particular species were available for testing. When <10 isolates were available, MIC range and percentage susceptibility calculations were reported according to CLSI 2020.8 The provisional tebipenem susceptibility breakpoint for Enterobacterales is ≤0.125 mg/L. There is no susceptibility breakpoint specified for tebipenem against GPO yet. Results The in vitro activity of tebipenem and six comparators against 300 GPO is depicted in Table 1 and Figure 1. The in vitro activity of tebipenem and six comparators against 311 GNB is depicted in Tables 2 and 3. Table 1. In vitro activity of tebipenem and comparator agents against GPO isolated from patients with cancerOrganismNo.Agent% SMIC (mg/L)MIC50MIC90Range Bacillus species20TebipenemNA 0.008 0.06 <0.004–0.25 Cefepime0.032>324 to >32Meropenem750.12580.03–8Levofloxacin1000.1250.1250.06–0.25Vancomycin1000.2510.06–2Daptomycin75180.125–16Linezolid100140.25–4 Corynebacterium species20TebipenemNA 0.06 0.125 0.008–1 Cefepime404>320.5 to >32Meropenem900.060.50.03–8Levofloxacin751160.06–32Vancomycin1000.250.50.06–2Daptomycin950.250.50.06–2Linezolid1000.250.50.06–2Vancomycin-susceptible E. faecalis35TebipenemNA 0.25 1 <0.004 to >4 Cefepime6>32>321 to >32Meropenem511>160.125 to >16Levofloxacin3732>320.5 to >32Vancomycin1001 1 0.25–2 Daptomycin37240.5–4Linezolid100240.5–4Vancomycin-susceptible E. faecium35TebipenemNA1>40.125 to >4Cefepime0.0>32>3232 to >32Meropenem0.016>162 to >16Levofloxacin2032>321 to >32Vancomycin100 0.5 1 0.06–2 Daptomycin14241–8Linezolid100121–4Vancomycin-resistant E. faecium20TebipenemNA>4>44 to >4Cefepime0.0>32>32>32Meropenem0.0>16>1616 to >16Levofloxacin0.032>3232 to >32Vancomycin0.0>32>3232 to >32Daptomycin10241–8Linezolid100 1 2 1–4 Micrococcus species20TebipenemNA <0.004 0.008 <0.004–0.015 Cefepime1000.060.125<0.03–0.125Meropenem1000.030.125<0.015–0.125Levofloxacin95120.25–16Vancomycin1000.1250.250.06–0.25Daptomycin1000.1250.250.06–0.5Linezolid1000.510.25–1MSSA40TebipenemNA 0.015 0.03 0.008–0.06 Cefepime33241–16Meropenem1000.1250.1250.03–0.25Levofloxacin800.25160.06 to >32Vancomycin1000.510.25–2Daptomycin950.2510.06–2Linezolid100121–4 S. lugdunensis 10TebipenemNA 0.03 0.25 0.03–0.5 Cefepime208162–32Meropenem1000.250.250.06–0.25Levofloxacin1000.25 0.25 0.125–0.5Vancomycin1000.50.50.25–1Daptomycin1000.250.50.125–0.5Linezolid1000.50.50.5–1β-Haemolytic streptococci (4 group A, 12 group B and 4 group G)20TebipenemNA <0.004 0.015 <0.004–0.125 Cefepime950.1250.250.06–4Meropenem1000.030.06 <0.015–0.125 Levofloxacin1000.510.06–1Vancomycin1000.1250.250.06–0.5Daptomycin1000.250.50.125–1Linezolid100120.125–2Group A β-haemolytic streptococci4TebipenemNANANA <0.004–0.125 Cefepime100NANA0.125–0.25Meropenem100NANA <0.015–0.125 Levofloxacin100NANA0.125–0.5Vancomycin100NANA0.06–0.25Daptomycin100NANA0.125–0.25Linezolid100NANA0.125–0.5Group B β-haemolytic streptococci12TebipenemNA <0.004 0.015 <0.004–0.015 Cefepime920.1250.50.06–4Meropenem1000.030.06<0.015–0.125Levofloxacin1000.510.25–1Vancomycin1000.1250.50.125–0.5Daptomycin1000.510.125–1Linezolid100120.5–2Group G β-haemolytic streptococci4TebipenemNA NA NA <0.004 Cefepime100NANA0.125–0.25Meropenem100NANA<0.015–0.03Levofloxacin100NANA0.06–0.25Vancomycin100NANA0.06–0.125Daptomycin100NANA0.125–0.25Linezolid100NANA0.5–1Penicillin-susceptible S. pneumoniae15TebipenemNA <0.004 0.015 <0.004–0.015 Cefepime1000.1250.50.06–0.5Meropenem1000.030.125<0.015–0.125Levofloxacin1000.2510.06–2Vancomycin1000.060.06<0.03–0.06Daptomycin1000.1250.250.06–0.5Linezolid1000.250.50.125–1Penicillin-resistant S. pneumoniae15TebipenemNA 0.015 0.06 <0.004–0.125 Cefepime870.540.125–8Meropenem930.510.06–4Levofloxacin532160.5–32Vancomycin1000.060.125<0.03–0.25Daptomycin1000.250.50.125–0.5Linezolid1000.50.50.25–1Viridans group streptococci25TebipenemNA 0.008 0.06 <0.004–0.125 Cefepime880.254<0.03–16Meropenem1000.031<0.015–1Levofloxacin84140.125–4Vancomycin1000.250.5<0.03–1Daptomycin1000.2510.06–1Linezolid1000.510.125–2 R. mucilaginosa 20TebipenemNA 0.015 0.125 0.008–0.125 Cefepime1000.510.06–2Meropenem1000.060.250.03–0.5Levofloxacin900.2520.06–4Vancomycin1000.2510.125–1Daptomycin1000.250.50.06–1Linezolid1000.510.25–1 Rhodococcus equi 5TebipenemNANANA 0.25–0.5Cefepime0NANA4 to >32Meropenem100NANA0.5–1Levofloxacin100NANA0.5–1Vancomycin100NANA 0.25–0.5 Daptomycin0NANA16 to >32Linezolid100NANA0.5–1Boldface indicates best MIC results. No., number of tested isolates; % S, percentage susceptibility; NA, not applicable, either because breakpoints have not been established for that antimicrobial/bacterium combination or because the antimicrobial is not expected to have activity for that bacterial species. FDA susceptibility breakpoints for tebipenem against GPO are not yet available In vitro activity of tebipenem and comparator agents against GPO isolated from patients with cancer Boldface indicates best MIC results. No., number of tested isolates; % S, percentage susceptibility; NA, not applicable, either because breakpoints have not been established for that antimicrobial/bacterium combination or because the antimicrobial is not expected to have activity for that bacterial species. FDA susceptibility breakpoints for tebipenem against GPO are not yet available Comparative MIC values between tebipenem and meropenem agents against 300 Gram-positive organisms. Table 2. In vitro activity of tebipenem and comparator agents against 311 GNB isolated from patients with cancerOrganismNo.Agent% SMIC (mg/L)MIC50MIC90Range Achromobacter species10TebipenemNA0.25 4 0.125 to >4CefepimeNA32>3216 to >32MeropenemNA0.25>4 0.06 to >4 SXTNA0.25/4.88/1520.125/2.4–16/304LevofloxacinNA2160.5–32AmikacinNA>64>642 to >64ErtapenemNA 0.125>4 0.06 to >4 Acinetobacter species10TebipenemNA0.5>40.125 to >4Cefepime801320.25 to >32Meropenem800.25>40.06 to >4SXT800.25/4.84/760.125/2.4–16/304Levofloxacin90 0.125 0.5 0.06–32 Amikacin100120.25–8ErtapenemNA>4>42 to >4 Citrobacter species15Tebipenem100 0.0150.06 ≤0.004–0.06 Cefepime870.254<0.03–16Meropenem100 0.015 0.03 0.008–0.06SXT870.125/0.68/1520.06/0.3–16/304Levofloxacin800.1258≤0.3 to >32Amikacin100120.125–4Ertapenem930.030.5≤0.004–1 K. aerogenes (known as E. aerogenes)21Tebipenem950.03 0.06 0.008–0.5 Cefepime95 ≤0.030.5≤0.03 to >32Meropenem950.03 0.06 0.008 to >4SXT950.25/1.20.25/1.20.125/0.6–8/152Levofloxacin95 ≤0.03 0.06 ≤0.3–4Amikacin95120.25–32Ertapenem900.060.25≤0.004 to >4 E. cloacae 30Tebipenem1000.03 0.125 0.008–0.125 Cefepime770.0632≤0.03 to >32Meropenem1000.030.060.008–0.25SXT770.5/2.4>32/6080.06/0.3 to >32/608Levofloxacin93 ≤0.030.25≤0.3–16Amikacin100120.25–2Ertapenem870.12510.015–2 E. coli, ESBL-producing isolates33Tebipenem100 0.015 0.03 0.008–0.125 Cefepime278>320.06 to >32Meropenem1000.030.060.015–0.25SXT42>32/608>32/6080.06/1.2 to >32/608Levofloxacin916>320.06 to >32Amikacin100480.5–16Ertapenem1000.060.50.008–0.5 E. coli, non-ESBL-producing isolates32Tebipenem100 0.008 0.015 ≤0.004–0.03 Cefepime90≤0.032≤0.03–32Meropenem100 0.008 0.015 ≤0.004–0.03 SXT561/19>32/608≤0.03/0.6 to >32/608Levofloxacin38832≤0.03 to >32Amikacin100240.5–16Ertapenem100 0.008 0.06 ≤0.004–0.25 K. oxytoca 30Tebipenem100 0.015 0.03 0.008–0.125 Cefepime730.0632≤0.03 to >32Meropenem100 0.0150.06 0.008–0.125SXT800.25/1.2>32/6080.06/0.3 to >32/608Levofloxacin870.061≤0.3 to >32Amikacin100120.25–8Ertapenem100 0.0150.1250.008–0.5 K. pneumoniae, ESBL-producing isolates35Tebipenem97 0.03 0.125 0.008–0.25Cefepime1116>320.06 to >32Meropenem100 0.03 0.125 0.008–0.125 SXT11>32/608>32/6080.25/1.2 to >32/608Levofloxacin348160.125–32Amikacin100140.25–8Ertapenem1000.060.250.015–0.25 K. pneumoniae, non–ESBL-producing isolates35Tebipenem1000.015 0.015 0.008–0.03Cefepime100≤0.030.125≤0.03–1Meropenem1000.0150.030.008–0.06SXT860.125/2.4>32/6080.06/1.2 to >32/608Levofloxacin890.061≤0.03–8Amikacin100110.25–4Ertapenem100 0.0080.03 ≤0.004–0.03 P. mirabilis 20Tebipenem1000.060.1250.015–0.125Cefepime900.061≤0.03 to >32Meropenem1000.03 0.06 0.015–0.125SXT550.5/2.4>32/6080.125/0.6 to >32/608Levofloxacin750.068≤0.3–16Amikacin654640.125 to >64Ertapenem100 0.015 0.06 0.008–0.0125 S. marcescens 20Tebipenem1000.060.1250.03–0.125Cefepime1000.1250.125≤0.03–0.5Meropenem100 0.03 0.06 0.03–0.06SXT1000.5/9.51/380.25/4.8–2/38Levofloxacin1000.060.1250.06–0.25Amikacin100241–4Ertapenem100 0.030.125 0.015–0.125 S. paucimobilis 10TebipenemNA0125 0.5 0.06–0.5 CefepimeNA2160.5–32MeropenemNA 0.06 0.5 0.03–1 SXTNA0.125/4.81/190.06/1.2–4/76LevofloxacinNA0.520.06–2AmikacinNA0.520.25–32ErtapenemNA140.06–4MDR and ESBL-producing E. coli10Tebipenem600.125>4 0.015 to >4 Cefepime0.0>32>32>32Meropenem60 0.06>40.125 to >4SXT0.0>32/608>32/6088/152 to >32/608Levofloxacin0.032>324 to >32Amikacin608324 to >64Ertapenem401>40.03 to >4Boldface indicates best MIC results. No., number of tested isolates; SXT, trimethoprim/sulfamethoxazole; % S, percentage susceptibility; NA, not applicable, either because breakpoints have not been established for that antimicrobial/bacterium combination or because the antimicrobial is not expected to have activity for that bacterial species. Provisional susceptibility breakpoint for tebipenem against Gram-negative Enterobacterales is ≤0.125 mg/L. In vitro activity of tebipenem and comparator agents against 311 GNB isolated from patients with cancer Boldface indicates best MIC results. No., number of tested isolates; SXT, trimethoprim/sulfamethoxazole; % S, percentage susceptibility; NA, not applicable, either because breakpoints have not been established for that antimicrobial/bacterium combination or because the antimicrobial is not expected to have activity for that bacterial species. Provisional susceptibility breakpoint for tebipenem against Gram-negative Enterobacterales is ≤0.125 mg/L. Table 3.Susceptibility (%) of 281 Enterobacterales isolates from patients with cancer to tebipenem and comparator agents for available US FDA breakpointsAgentsTebipenemFEPMEMSXTLVXAMKETPBreakpoint for Enterobacterales isolates (mg/L)≤ 0.125≤ 2≤ 1≤ 2≤ 0.5≤ 16≤ 0.5 Citrobacter spp. (n = 15)100.086.7100.086.780.0100.093.3 E. aerogenes (n = 21)95.295.295.295.295.295.290.5 E. cloacae (n = 30)100.076.7100.076.793.3100.086.7 E. coli, ESBL-producing isolates (n = 33)100.027.3100.042.49.1100.0100.0 E. coli, non-ESBL-producing isolates (n = 32)100.093.6100.056.337.5100.0100.0 K. oxytoca (n = 30)100.073.3100.080.086.7100.0100.0 K. pneumoniae, ESBL-producing isolates (n = 35)97.111.4100.011.434.3100.0100.0 K. pneumoniae, non-ESBL-producing isolates (n = 35)100.0100.0100.085.788.6100.0100.0 P. mirabilis (n = 20)100.090.0100.055.075.065.0100.0 Serratia spp. (n = 20)100.0100.0100.0100.0100.0100.0100.0 E. coli, MDR and ESBL-producing isolates (n = 10)60.00.060.00.00.060.040.0Total of susceptible isolates/total tested275/281193/281276/281177/281179/281269/281268/281Susceptible (%)98.069.098.063.064.096.095.0FEP, cefepime; MEM, meropenem; SXT, trimethoprim/sulfamethoxazole; LVX, levofloxacin; AMK, amikacin; ETP, ertapenem. Susceptibility (%) of 281 Enterobacterales isolates from patients with cancer to tebipenem and comparator agents for available US FDA breakpoints FEP, cefepime; MEM, meropenem; SXT, trimethoprim/sulfamethoxazole; LVX, levofloxacin; AMK, amikacin; ETP, ertapenem. Activity against GPO Although the FDA does not yet have tebipenem breakpoints for GPO, tebipenem had low MIC90 and MIC range for GPO, except for Enterococcus isolates. At a concentration of ≤0.125 mg/L, tebipenem inhibited all tested isolates (100%) of Micrococcus species, MSSA, β-haemolytic streptococci, Streptococcus pneumoniae (penicillin-resistant and -susceptible isolates), viridans group streptococci and Rothia mucilaginosa. Tebipenem inhibited 95% of Bacillus and 90% of Corynebacterium species at an MIC of ≤0.125 mg/L. Linezolid and vancomycin showed the most activity among comparators against vancomycin-susceptible Enterococcus isolates, and linezolid was the most active agent against vancomycin-resistant Enterococcus faecium, with 100% susceptibility. In addition, tebipenem showed low MIC ranges relative to comparators when tested against MSSA, Staphylococcus lugdunensis, β-haemolytic streptococci, S. pneumoniae isolates, viridans group streptococci, R. mucilaginosa, Bacillus, Corynebacterium and Micrococcus species. Comparative MIC values (mg/L) between tebipenem and meropenem against the 300 GPO tested in the current study are shown in Figure 1. At the susceptibility point of meropenem (≤1 mg/L), meropenem inhibited 220 of 300 isolates (73%), whereas tebipenem inhibited 260 of 300 strains (87%). In addition, at MIC values as low as ≤0.015 mg/L, tebipenem inhibited 152 isolates (51%), whereas meropenem inhibited only 18 (6%) of all 300 tested GPO. Activity against GNB The in vitro activity of tebipenem and comparator agents against 311 GNB is shown in Tables 2 and 3. Activity against Enterobacterales Overall, 275 of 281 isolates (98%) with available breakpoints were susceptible to tebipenem. At ≤0.125 mg/L concentration, tebipenem inhibited 100% of tested isolates of Enterobacter cloacae, E. coli (non-ESBL-producing strains), Klebsiella oxytoca, non-ESBL Klebsiella pneumoniae, Proteus mirabilis, Serratia marcescens and Citrobacter species. Furthermore, tebipenem inhibited 20 of 21 (95%) Klebsiella aerogenes isolates (known as Enterobacter aerogenes), 34 of 35 (97%) ESBL-producing K. pneumoniae isolates, and 6 of 10 (60%) MDR and ESBL-producing E. coli. Tebipenem was similar to meropenem and ertapenem when tested against 281 Enterobacterales isolates with known breakpoints. In contrast, the susceptibility rates of these organisms to levofloxacin and cefepime were 64% and 69%, respectively. Activity against non-fermentative GNB Although susceptibility breakpoints for non-fermentative GNB are not currently available, the MIC90 values of tebipenem for Sphingomonas paucimobilis, Achromobacter and Acinetobacter species were 0.5, 4.0 and >4.0 mg/L, respectively. Most of these isolates (22 of 30; 73%) were inhibited by tebipenem at a concentration of ≤0.5 mg/L. Discussion Our data showed that tebipenem had excellent antibacterial activity against most isolates of a diverse array of GNB that recently caused serious infections in patients with cancer. These results are consistent with the results of other investigations that did not specifically focus on isolates from patients with cancer.9,10 Although the FDA does not yet have breakpoints for tebipenem against GPO, tebipenem had low MIC90 and MIC ranges among all tested comparators against tested GPO, except Enterococcus isolates. Tebipenem also inhibited most of the tested GPO at the low MIC values compared with MEM and other antimicrobials. Several published studies support these findings.11,12 Bacterial resistance to antimicrobial agents is increasing, with increasing rates of infections caused by ESBL-producing and fluoroquinolone-resistant Enterobacterales.13 Although antimicrobial resistance to carbapenems remains as low as <2%,13,14 all currently approved and available carbapenems in the USA and Europe are parenteral. Hence, there is a need for effective oral treatment options for patients with antimicrobial-resistant pathogens such as ESBL-producing organisms. The available oral antimicrobial agents active against ESBL-producing organisms are also limited. This could be due to poor tissue penetration and low plasma concentrations, as is the case for nitrofurantoin and fosfomycin, and this may predispose patients to treatment failure and selection of bacterial resistance.15,16 Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem that is rapidly converted to the active form by enterocytes.17 In a recent large prospective randomized clinical trial, Eckburg et al.18 showed that tebipenem pivoxil hydrobromide was non-inferior to IV ertapenem in the treatment of complicated urinary tract infection or acute pyelonephritis, with a similar safety profile.18 Other in vivo studies conducted in animal models showed that tebipenem is highly efficacious for the treatment of soft-tissue, pulmonary and urinary tract infections.19,20 These in vivo studies and the clinical trial, in addition to the current study, indicate that tebipenem could have a promising clinical application in the treatment of various infections caused by resistant organisms. Organisms retrieved from immunosuppressed patients with cancer tend to be more resistant because these patients are usually exposed to prolonged prophylactic and empirical antimicrobial therapy. Our data confirm that tebipenem is active against most GPO and GNB pathogens, except for P. aeruginosa and MRSA, recovered from patients with cancer and not tested in the current study. The lack of activity of tebipenem against these two highly pathogenic organisms limits its use as empirical monotherapy in febrile neutropenic patients, particularly patients who require MRSA coverage such as those with suspected catheter-related infection, skin or soft tissue infection, pneumonia or haemodynamic instability. However, tebipenem could be used in combination with a fluroquinolone such as delafloxacin for empirical outpatient therapy in low-risk febrile neutropenic patients.21 Additionally, tebipenem could be highly useful in cancer patients as step-down targeted therapy against isolated or mixed pathogens (particularly resistant organisms such as ESBL-producing or AmpC β-lactamase GNB, in the absence of pseudomonal infections. This could facilitate early discharge from the hospital and avoid prolonged IV antimicrobial therapy, particularly in patients with underlying neutropenia or deep-seated infection. Such an approach would be in line with recent trials, which demonstrated a successful transition from IV to oral antibiotics in patients with bone and joint infections or infective endocarditis that traditionally required prolonged IV antibiotic therapy.22,23 Our results showed that S. pneumoniae had an unusual increased resistance to levofloxacin (47%), while previous studies showed less than 3% resistance. This may be due to the fact that many of our cancer patients are at high risk of infections and often receive fluoroquinolones for infection prophylaxis during prolonged periods of chemotherapy-induced neutropenia.24,25 Our study had several limitations. Although we reported MIC, we didn’t perform time–kill experiments, and therefore could not relate expected clinical activity to achievable plasma concentrations, particularly in light of pharmacokinetic studies that suggest decline of tebipenem plasma concentrations following dosage administration.26 Another limitation is that this was strictly a laboratory study. The isolates collected and tested were de-identified, hence we did not have demographic information on the patients. This may limit the applicability of our results in vivo. Futures studies that would describe patients’ characteristics and outcomes could provide valuable information to guide the selection of empirical therapy for difficult-to-treat infections in this vulnerable patient population. In conclusion, our data show that oral tebipenem has promising activity against clinically significant GPO and GNB pathogens isolated from patients with cancer and tebipenem has similar potency to that of other widely used parenteral carbapenems, such as meropenem and ertapenem, in cancer patients. Further clinical evaluation for oral carbapenem treatment of bacterial infections in patients with cancer is warranted if oral dosing regimens can sustain sufficiently high plasma concentrations. Acknowledgements We thank Ms. Sally Saxton for her help in submitting this manuscript, and Ms. Erica Goodoff in the Research Medical Library at The University of Texas MD Anderson Cancer Center for editing the manuscript. Contributor Information Bahgat Gerges, Department of Infectious Diseases, Infection Control and Employee Health Research, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Blvd, Houston, TX 77030, USA. Joel Rosenblatt, Department of Infectious Diseases, Infection Control and Employee Health Research, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Blvd, Houston, TX 77030, USA. Samuel A Shellburne, Department of Infectious Diseases, Infection Control and Employee Health Research, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Blvd, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Blvd, Houston, TX 77030, USA. Anne-Marie Chaftari, Department of Infectious Diseases, Infection Control and Employee Health Research, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Blvd, Houston, TX 77030, USA. Ray Hachem, Department of Infectious Diseases, Infection Control and Employee Health Research, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Blvd, Houston, TX 77030, USA. Issam Raad, Department of Infectious Diseases, Infection Control and Employee Health Research, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Blvd, Houston, TX 77030, USA. Funding This study was supported in part by Tetraphase Pharmaceuticals Transparency declarations None to declare. Author contributions Conceptualization and design: B.G., J.R., I.R.; budget preparation and originating the project: B.G., A.C., R.H., I.R.; project administration: B.G., J.R., I.R.; laboratory methodology and support: B.G., J.R., S.A.S., I.R.; writing original draft: B.G.; review, and editing: A.C., R.H., J.R., I.R.; supervision: I.R.. All authors reviewed and finalized the manuscript. References